Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01469208
Other study ID # 1110096A
Secondary ID
Status Recruiting
Phase N/A
First received November 8, 2011
Last updated July 31, 2013
Start date October 2011
Est. completion date December 2014

Study information

Verified date July 2013
Source Children's Hospitals and Clinics of Minnesota
Contact Catherine T Worwa, LRT, BS, CCRP
Phone 612-813-6864
Email cathy.worwa@childrensmn.org
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The investigators hope to determine if music therapy will have beneficial effects on physiologic parameters, behavioral states, and pain scale evaluations in infants with gastroschisis defects and if music therapy promotes parental/caregiver relaxation and demonstrates to the parent/caregiver that music is an effective tool to calm and soothe their infant at risk for chronic gastrointestinal discomfort.

Babies will be enrolled during the perinatal period, with therapy to begin after surgical repair of the gastroschisis defect and when the neonatologist deems the baby stable enough for music therapy intervention. Enrolled subjects may receive up to 3 music therapy sessions/week and these sessions may continue until discharge. There is no follow up after discharge.

Each one hour session (20-30 minutes of music and 30 minutes of quiet) will include:

1. Pre music therapy behavior state will be assessed using CRIES scale and recorded.

2. Five minutes of baseline vital signs will be recorded.

3. Music therapy lasting 20-30 minutes, will start. Music therapist will use guitar and lap harp to perform live lullaby tupe music with or with out vocals. Decibel levels will be maintained at 65-75dB. Session will stop if infant shows any signs of distress/agitation. Vital signs will be collected every 1-4 minutes during music session.

4. After session behavior state using CRIES scale will be recorded.

5. Family/caregiver will be given a questionnaire to fill out.

6. 30 min of quiet will start.

7. At the end of quiet time, behavior state and vital signs will be recorded for the last time.


Description:

Prior to starting the music therapy session, family/caregivers, if present, will be informed of study session progression. They will be reminded of appropriate behavioral protocol to maintain therapeutic environment during session - i.e. minimal taking & touching, cell phones off etc. A "Do Not Disturb - Music Therapy Session in Progress" will be posted outside pts room on the door.

Behavioral state data and vitals signs collected during sessions will be entered into a database. Also recorded, will be general information about the baby and its mother, such as, gestational age, apgar scores, mothers age and race, number of days post surgical repair etc.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 2014
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender Both
Age group N/A to 6 Months
Eligibility Inclusion Criteria:

1. Diagnosis of Gastroschisis

2. Patient is stable enough to receive music therapy as determined by Neonatologist

3. Patient has passed their newborn hearing screen

Exclusion Criteria:

1. Neonatologist feels patient/family would not be an acceptable research candidate.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
United States Childrens Hospitals and Clinics of MN Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Children's Hospitals and Clinics of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Music Therapy will produce stable physiologic, states as well as, positive behavior states Vital signs monitor data and stress assessment scores will be collected before, during and post Music Therapy sessions 3 years No
See also
  Status Clinical Trial Phase
Completed NCT00539292 - Evaluating the Use of a Silastic Spring-Loaded Silo for Infants With Gastroschisis Phase 2
Recruiting NCT03724214 - Multi-Centre Gastroschisis Interventional Study Across Sub-Saharan Africa N/A
Terminated NCT00404690 - Bedside Silo Versus Operative Closure for Gastroschisis N/A
Recruiting NCT05704257 - Fetal Repair of Complex Gastroschisis: A Safety and Feasibility Trial N/A
Completed NCT03533439 - Regional Blood Saturation Levels in Gastroschisis
Active, not recruiting NCT03393832 - Oral Care in Infants With Gastroschisis
Completed NCT03666767 - Management and Outcomes of Congenital Anomalies in Low-, Middle- and High-Income Countries
Terminated NCT03355326 - Evaluation of Glycerin Suppositories to Improve Bowel Function in Gastroschisis Phase 4
Completed NCT03185637 - Children's Surgery in Sub-Saharan Africa N/A
Completed NCT02575846 - Clinical and Biological Outcomes of Human Milk and Formula Intake After Gastroschisis Repair N/A
Terminated NCT01094587 - Sutureless vs Sutured Gastroschisis Closure N/A
Active, not recruiting NCT00127946 - Trial of AMNIOECHANGE in Gastroschisis Affected Foetuses Phase 3
Withdrawn NCT04186039 - Functional Evaluation of the Fetal Lung by Functional Magnetic Resonance Imaging - Blood Oxygenation Level Dependent (MRI-BOLD), in Congenital Diaphragmatic and Parietal Malformations N/A
Completed NCT03960320 - Health Related Quality of Life of Patients With Abdominal Wall Defects
Terminated NCT02098915 - Metoclopramide Pilot Trial Phase 3
Completed NCT01316510 - Probiotics in Infants With Gastroschisis N/A
Completed NCT04020939 - The Role of Indocyanine Green Angiography Fluorescence on Intestinal Resections in Pediatric Surgery. N/A
Recruiting NCT06072976 - The Influence of Feeding Source on the Gut Microbiome and Time to Full Feeds in Neonates With Congenital Gastrointestinal Pathologies N/A
Recruiting NCT05293353 - Neokare Safety and Tolerability Assessment in Neonates With GI Problems
Completed NCT02370251 - Compassionate Use of Omegaven in Children Phase 2/Phase 3